高位肌间沟神经阻滞用于锁骨骨折手术麻醉临床疗效

目的:高位肌间沟神经阻滞用于锁骨骨折手术麻醉临床疗效.方法:选取我院收治的锁骨骨折手术患者60例进行实验,选取时间2018年9月-2020年9月,根据麻醉方法不同分为2组,各30例.参照组采用常规臂丛神经麻醉的方法,实验组采用高位肌间沟神经阻滞麻醉处理的方法,观察两组患者的麻醉效果.结果:两组患者在麻醉优良率的对比上存...     

“读经典、学名著”大型读书活动专题辅导——《针灸大成》学习辅导题（二）

一.填空题1.《针灸大成·席弘赋》记载冷嗽的治疗宜先____,再____。2.在《针灸大成》中记载的“马丹阳天星十二穴”包括____、____、____、____、____、____、____、____、____、____、____、____。与《扁鹊神应针灸玉龙经》记载的“天星十一穴”相比,多出一穴为____。3.四总穴     

DC-CIK过继性免疫疗法联合化疗治疗转移性结直肠癌患者的疗效

目的： 研究DC-CIK（dendritic cell-cytokine induced killer cell）过继性免疫治疗联合化疗对转移性结直肠癌（metastatic colorectal cancer,mCRC）的疗效及安全性。 方法： 选取2010年11月至2011年11月在大连市中心医院治疗的80例mCRC患者,40例行DC-CIK治疗联合化疗（联合组）,40例行单纯化疗（化疗组）,评价两组患者治疗后免疫功能、疗效、毒副反应和生活质量（quality of life,QOL)。 结果： 共完成了160周期DC-CIK治疗,联合组治疗前后外周血T细胞亚群无显著变化（P>0.05）,化疗组治疗后外周血中CD3+、CD3+CD4+、CD3+CD8+、CD3-CD56+细胞比例较治疗前显著下降,且明显低于联合组（P<0.05）;联合组3周期治疗后CD4+ T细胞中IFN-γ水平较治疗前显著升高（P<0.05）,化疗组治疗后IFN-γ、IL-2、TNF-α水平著下降,且明显低于联合组（P<0.05）。联合组和化疗组总有效率（response rate, RR）未见明显差异（37.5% vs 22.5%,P>0.05）;联合组疾病控制率（disease control rate,DCR）明显高于化疗组（77.5% vs 50.0%,P<0.05）。联合组Ⅲ～Ⅳ度白细胞减少及Ⅲ～Ⅳ度迟发性腹泻的发生率明显低于化疗组（17.5% vs 42.5%,5.0% vs 25.0;均P<0.05）,其他相关不良反应无显著性差异,而且对症治疗后均可缓解。联合组患者的中位无进展生存（progression-free survival,PFS）较化疗组患者长（6.5个月 vs 4.5个月,P<0.05）,联合组和化疗组患者的总生存（overall survival,OS）比较差异无统计学意义（P>0.05）。联合组在躯体功能、情绪方面较治疗前明显改善,而且明显好于化疗组（P<0.05）。 结论： DC-CIK过继性免疫治疗联合化疗可以明显改善mCRC患者的免疫功能,提高总体疗效,减轻化疗不良反应,延长无进展生存,改善mCRC患者生活质量。     

脂肪抑制素对宫颈癌细胞增殖、克隆形成、侵袭、迁移的抑制作用及相关机制研究

目的:探究脂肪抑制素对宫颈癌细胞增殖、克隆形成能力、侵袭及迁移能力以及细胞周期、细胞凋亡的影响.方法:选取宫颈癌细胞系SiHa,利用不同浓度脂肪抑制素进行培养.通过MTT实验、平板克隆形成实验、Transwell实验及流式细胞术检测实验分别检测脂肪抑制素对宫颈癌细胞增殖、克隆形成能力、侵袭/迁移能力以及细胞周期/细胞凋...     

Acupuncture for allergic rhinitis: a systematic review and meta analysis

Objective

To analyze and review the clinical efficacy of acupuncture (including electroacupuncture) alone for allergic rhinitis (AR) and to compare its efficacy with antihistamines and Chinese patent medicine Bi Yan Kang Tablet.

Methods

The search strategy, inclusion and exclusion criteria were made according to the principle of evidence-based medicine. We performed a systematic search on China National Knowledge Infrastructure (CNKI), Wanfang Academic Journal Full-text Database (Wanfang), Chongqing VIP Database (CQVIP), Chinese Biomedical Literature Database (CBM), PubMed, Excerpta Medica Database (EMBASE), Web of Science, Cochrane Library, and Cochrane Central Register of Controlled Trials (CENTRAL) for randomized controlled trials (RCTs) of acupuncture for allergic rhinitis between January 1990 and December 2015. The quality was evaluated by Cochrane Handbook for Systematic Reviews of Interventions Version 5.1, and the meta-analysis was conducted by RevMan 5.3 version.

Results

Twenty eligible RCTs were included into the meta-analysis after selection. Compared with antihistamines, the meta-analysis showed RR=1.24>1, 95%CI[1.15, 1.33], P<0.00001, indicating that acupuncture achieved a better total effective rate for AR than antihistamines; MD = –0.93<0, 95%CI[–1.22,–0.63], P<0.00001, indicating that acupuncture is better than antihistamines in decreasing the total nasal symptom score (TNSS) in AR patients; and MD = 1.46>0, 95%CI[–10.84, 13.75], P = 0.82, indicating that there was no statistical difference between acupuncture and antihistamines in regulating immunoglobulin E (IgE) in AR patients. Compared with Bi Yan Kang Tablet, the meta-analysis has shown RR = 1.50>1, 95%CI[1.30, 1.73], P<0.00001, indicating that acupuncture achieved a better total effective rate for AR than Chinese patent medicine Bi Yan Kang Tablet.

Conclusion

Acupuncture alone can achieve a better total effective rate for AR than antihistamines and Bi Yan Kang Tablet. It is also better than antihistamines in improving clinical symptom scores; however, whether acupuncture is better than Bi Yan Kang Tablet needs further proof. As far as current data are concerned, there was no statistical difference between acupuncture and antihistamines in improving serum IgE; further study is needed in this regard. The risk of bias due to absent randomization methods or blinding implementation decreased the evidence level of the overall conclusion.

     

PKCβⅡ与NF-κBp50在乳腺癌组织中表达及其意义

目的探讨蛋白激酶CβⅡ(Protein Kinase CβⅡ,PKCβⅡ)和核因子κBp50(Nuclear FactorκappaBp50,NF-κBp50)在乳腺癌组织中表达及其意义。方法应用免疫组织化学方法检测67例乳腺癌和14例乳腺良性病变石蜡组织标本中PKCβⅡ与NF-κBp50表达情况,分析两指标与临床病理特征的关系。结果 PKCβⅡ在乳腺癌、不典型增生和乳腺腺病组织中阳性表达率分别为95.50%(64/67)、50.00%(3/6)和50.00%(4/8);而NF-κBp50阳性表达率分别为86.60%(58/67)、66.70%(4/6)和75.00%(6/8);乳腺癌和乳腺良性病变中PKCβⅡ和NF-κBp50比较差异有统计学意义(P<0.05)。NF-κBp50表达与乳腺癌淋巴结有无转移差异有统计学意义(P<0.05)。乳腺癌组织中PKCβⅡ和NF-κBp50阳性表达呈正相关(rs=0.29,P<0.05)。结论 PKCβⅡ和NF-κBp50在乳腺癌组织中高表达与乳腺癌的发生、发展和转移有关。     

不同剂量疏血通对冠心病心绞痛的疗效与安全性观察

目的 探讨不同剂量疏血通对冠心病心绞痛的疗效与安全性.方法 90例资料齐全的冠心病心绞痛患者,分为对照组(A组)、疏血通6 mL治疗组(B组)、疏血通10 mL治疗组(C组),三组患者均给予正规基础治疗(包括ACEI、β-受体阻滞剂、硝酸酯类、阿司匹林、调脂药等),比较三组在治疗前后心绞痛发作次数、持续时间,非致死性心肌梗死,心源性死亡,心电图改变等指标.结果 B组和C组治疗后在心绞痛发作次数、持续时间、心电图改变等方面均优于A组(P<0.05):而C组在各项指标上优于B组(P<0.05).结论 疏血通可显著减少冠心病心绞痛发作次数,缩短发作时间,改善心电图缺血表现,较大剂量疏血通疗效更好,且安全无副作用.     

腓肠神经营养血管蒂岛状皮瓣修复足部软组织缺损

目的 探讨腓肠神经营养血管蒂岛状皮瓣治疗足部皮肤软组织缺损的临床效果.方法 根据足部皮肤软组织缺损的形状、面积设计腓肠神经营养血管岛状皮瓣,旋转点最低在外踝尖上5cm,修复15例创面.结果 术后15例皮瓣全部成活,其中1例皮瓣远端小片皮肤坏死,经换药后愈合.结论 腓肠神经营养血管岛状皮瓣成活率高,感觉恢复好,皮肤质量较好,切取简便,创伤小,效果好,是修复足部较大面积皮肤软组织缺损的一种理想皮瓣.